FDC Ltd. News, Corporate filings and Earnings/Conference Calls

Pharmaceuticals company FDC announced Q2FY24 & H1FY24 results: Q2FY24: Operating Revenue: Rs 486 crore, a solid 9.3% YoY growth. EBITDA: Rs 76 crore, up by 13.5% YoY. EBITDA Margin: 15.2%. PBT: Rs 93 crore, a notable 34.3% YoY increase. PAT: Rs 70 crore, showing a strong 34.7% YoY growth. EPS: Rs 4.22, with a significant 36.2% YoY increase. H1FY24: Operating Revenue: Rs 1,023 crore, an 8.8% YoY growth. EBITDA: Rs 198 crore, a substantial 36.5% YoY increase. EBITDA Margin: 19.4%. PBT: Rs 233 crore, with a remarkable 49.6% YoY growth. PAT: Rs 180 crore, showing a notable 46.7% YoY increase. EPS: Rs 10.84, with a strong 47.5% YoY growth. Commenting on the results, the company said, "During Q2FY24 and H1FY24, we are pleased to announce that we have achieved growth across all our business segments in Domestic as well as International business. The major driver growth in the Domestic Formulation business is laid by the flagship brands, Electral, Zifi, Enerzal and Zifi-O. Growth in the International Formulation business is primarily laid by the US market growing by 31.7% during H1FY24. Further, the margins and profitability have shown significant improvements during the quarter as well as H1FY24 attributable primarily to improved sale realisation, lower cost of goods sold, and lower operating expenses." Result PDF

35.52% Gain from 52W Low

FDC Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on FDC Ltd. from all sources in a single place.